SCHEMBL3924475

SCHEMBL3924475

CCOC(=O)[C@H](Cc1ccc(O)cc1)NS(=O)(=O)c1ccc(-c2ccccc2)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 1/20 0.73
MMP2 P08253 10/20 0.62
MMP9 P14780 6/20 0.62
ADAMTS4 O75173 2/20 0.62
MEN1 O00255 2/20 0.57
KMT2A Q03164 2/20 0.57
L3MBTL1 Q9Y468 2/20 0.57
MMP13 P45452 2/20 0.56
ADAMTS5 Q9UNA0 1/20 0.56
MMP1 P03956 1/20 0.56
MMP3 P08254 1/20 0.56
MMP7 P09237 1/20 0.56
CTSL P07711 2/20 0.53
CTSS P25774 1/20 0.53
ALDH1A1 P00352 1/20 0.50
MAPT P10636 1/20 0.50
MMP14 P50281 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
POLB P06746 1/20 0.50
F2 P00734 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3926872 0.89 BACE1 (0.71) BACE1MMP2MMP9ADAMTS4MEN1
SCHEMBL10914560 0.89 BACE1 (0.71) BACE1MMP2MMP9ADAMTS4MEN1
SCHEMBL3936334 0.87 BACE1 (0.68) BACE1MMP2MMP9ADAMTS4MEN1
SCHEMBL3923618 0.87 BACE1 (0.68) BACE1MMP2MMP9ADAMTS4MEN1
SCHEMBL3935023 0.86 BACE1 (0.67) BACE1MMP2MMP9ADAMTS4MEN1
SCHEMBL7755592 0.86 BACE1 (0.67) BACE1MMP2MMP9ADAMTS4MEN1
SCHEMBL3927017 0.85 BACE1 (0.76) BACE1POLBF2
SCHEMBL30689128 0.85 CTSL (0.63) BACE1MMP2MMP9ADAMTS4MEN1
SCHEMBL7984123 0.84 POLB (0.60) BACE1MMP2MMP9ADAMTS4MEN1
SCHEMBL15943338 0.83 MMP2 (0.75) MMP2MMP9ADAMTS4MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1076557-A1 CCR-3 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2001-02-21 EP claimed
WO-1999055324-A1 CCR-3 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1999-11-04 WO claimed
EP-1691199-B1 METHOD OF PREDICTING SPOT FORMATION ON THE SKIN WITH THE USE OF SPOT SITE-ACCELERATING GENES AS INDICATION AND METHOD OF SCREENING INHIBITOR FOR SPOT FORMATION ON THE SKIN SHISEIDO CO LTD (JP) 2009-04-01 EP disclosed
US-20070249915-A1 Inhibitors SHISEIDO COMPANY, LTD. (JP) 2007-10-25 US disclosed
EP-1691199-A1 METHOD OF PREDICTING SPOT FORMATION ON THE SKIN WITH THE USE OF SPOT SITE-ACCELERATING GENES AS INDICATION AND METHOD OF SCREENING INHIBITOR FOR SPOT FORMATION ON THE SKIN SHISEIDO COMPANY LIMITED (JP) 2006-08-16 EP disclosed
EP-1076557-A1 CCR-3 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2001-02-21 EP disclosed
WO-1999055324-A1 CCR-3 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1999-11-04 WO disclosed